NUR 600 Advanced Clinical Pharmacology Actual Exam –
Graduate Nursing Program – 2026/2027 Academic Year EXAM
with Questions and Answers/Plus a Rationale Updated 2026
A+/Instant Download PDF
EXAM COVERAGE - 1. Pharmacokinetics and Pharmacodynamics in Advanced
Practice - 2. Autonomic and Central Nervous System Pharmacology - 3.
Cardiovascular and Renal Pharmacotherapeutics - 4. Endocrine and Metabolic
Pharmacology - 5. Antimicrobial Stewardship and Anti-infective Therapy - 6.
Psychopharmacology and Neurotransmitter Systems - 7. Immunopharmacology and
Oncologic Agents - 8. Pediatric, Geriatric, and Pregnant Population Pharmacotherapy
- 9. Toxicology, Adverse Drug Reactions, and Drug-Drug Interactions - 10. Evidence-
Based Prescribing and Regulatory Standards
1. A 68-year-old patient with chronic kidney disease stage 4 (eGFR 24 mL/min/1.73m2) is prescribed a new
medication that is 90% eliminated unchanged by the kidneys. Assuming normal liver function and a
standard adult loading dose, what is the most critical pharmacokinetic alteration expected in this patient?
A. Decreased volume of distribution due to hyperalbuminemia
B. Prolonged elimination half-life and risk of drug accumulation
C. Accelerated hepatic clearance via induction of CYP450 enzymes
D. Decreased time to reach steady-state concentration due to enhanced renal clearance
CORRECT ANSWER : B
Rationale: Renal impairment significantly reduces the clearance of drugs primarily excreted by the kidneys,
which directly increases the elimination half-life and leads to drug accumulation if the maintenance dose or
dosing interval is not adjusted. Volume of distribution and hepatic clearance are distinct physiological
parameters not directly accelerated by renal failure, and time to steady state is prolonged rather than
decreased.
2. A patient is prescribed a narrow therapeutic index drug that is a substrate for CYP3A4. Two days later, a
potent CYP3A4 inhibitor is added to their therapeutic regimen. What immediate clinical pharmacological
adjustment must the advanced practice nurse anticipate?
A. Increase the dose of the substrate drug to overcome enzyme inhibition
B. Decrease the dose or monitor serum drug levels closely to prevent toxicity
C. Switch the substrate drug to a prodrug requiring CYP3A4 activation
, D. Discontinue monitoring because inhibition decreases steady-state fluctuations
CORRECT ANSWER : B
Rationale: Inhibition of CYP3A4 decreases the metabolic breakdown of the substrate drug, raising its
plasma concentration and increasing the risk of adverse toxic effects, particularly with narrow therapeutic
index medications. Increasing the dose would exacerbate toxicity, while switching to a prodrug or
abandoning monitoring would compromise patient safety.
3. Which of the following describes the primary mechanism of action of a competitive antagonist at a G-
protein coupled receptor?
A. It binds irreversibly to the active site, permanently reducing receptor density
B. It binds to an allosteric site to induce a conformational change that prevents agonist binding
C. It binds reversibly to the active site, shifting the agonist dose-response curve to the right without
changing the maximal efficacy
D. It constitutively activates the intracellular signaling cascade independent of agonist presence
CORRECT ANSWER : C
Rationale: A competitive antagonist reversibly binds to the same active site as the agonist, meaning high
concentrations of the agonist can overcome the antagonism, shifting the dose-response curve to the right
while preserving maximal efficacy. Irreversible binding describes noncompetitive antagonism, allosteric
binding describes allosteric modulation, and constitutive activation describes inverse agonism or agonism.
4. A patient with severe hypertension is treated with a drug that exhibits zero-order elimination kinetics at
therapeutic doses. What is the defining characteristic of zero-order elimination that the clinician must
consider?
A. A constant fraction of the drug is eliminated per unit of time regardless of plasma concentration
B. A constant amount of drug is eliminated per unit of time, which can lead to disproportionate
plasma level increases with dose increments
C. The elimination half-life remains strictly proportional to the plasma concentration at any given moment
D. The rate of elimination is entirely dependent on the instantaneous volume of distribution
CORRECT ANSWER : B
Rationale: Under zero-order elimination, elimination mechanisms become saturated, meaning a constant
amount of drug is cleared per unit of time rather than a constant percentage. This nonlinear clearance can
, cause a disproportionate, potentially toxic increase in plasma concentrations with small dosage increases.
Constant fraction elimination defines first-order kinetics.
5. An advanced practice registered nurse is evaluating a drug with a high hepatic extraction ratio (greater than
0.7). Which clinical factor will most significantly influence the systemic bioavailability of this oral
medication?
A. Plasma protein binding capacity of the drug in the systemic circulation
B. Changes in hepatic blood flow rather than alterations in CYP enzyme activity
C. The pH of the distal convoluted tubule in the renal nephron
D. Competitive inhibition by plasma cholinesterases
CORRECT ANSWER : B
Rationale: Drugs with a high hepatic extraction ratio undergo extensive first-pass metabolism, making their
systemic bioavailability primarily dependent on the rate of hepatic blood flow rather than intrinsic enzymatic
capacity. Plasma protein binding and renal tubular pH affect distribution and elimination rather than oral
first-pass clearance.
6. A clinical trial investigates a novel partial agonist. Compared to a full agonist acting on the same receptor
population, what is the defining pharmacodynamic property of a partial agonist?
A. It produces zero intrinsic activity regardless of receptor occupancy
B. It elicits a submaximal maximal response even when 100 percent of the receptors are occupied
C. It acts exclusively through intracellular second-messenger degradation
D. It displays an infinite affinity for the inactive receptor conformation
CORRECT ANSWER : B
Rationale: A partial agonist binds to receptors but produces lower intrinsic efficacy and submaximal
maximum response compared to a full agonist, even at full receptor occupancy. It can also act as a
competitive antagonist in the presence of a full agonist by occupying binding sites.
7. In managing a patient with acute heart failure, a drug is administered via continuous intravenous infusion.
Approximately how many elimination half-lives are required to achieve 97 percent of the steady-state
plasma concentration?
A. One half-life
B. Three half-lives
, C. Five half-lives
D. Ten half-lives
CORRECT ANSWER : C
Rationale: Pharmacokinetically, a drug reaches approximately 97 percent of its steady-state concentration
after five elimination half-lives (representing 1 minus (0.5 to the 5th power), or 96.875 percent). One half-life
reaches 50 percent, and three half-lives reach roughly 87.5 percent.
8. When calculating the loading dose for an emergency administration of an antiarrhythmic agent, which
pharmacokinetic parameters are mathematically required?
A. Clearance and elimination half-life
B. Target peak plasma concentration and volume of distribution
C. Renal excretion rate and protein binding percentage
D. Minimum effective concentration and hepatic extraction ratio
CORRECT ANSWER : B
Rationale: The formula for a loading dose is the desired target plasma concentration multiplied by the
apparent volume of distribution. Clearance and half-life dictate the maintenance dosage regimen rather
than the initial loading dose.
9. A patient is administered a medication that undergoes extensive Phase II glucuronidation prior to excretion.
Which cellular organelle and enzyme system are primarily responsible for this metabolic process?
A. Mitochondria and monoamine oxidase
B. Endoplasmic reticulum and uridine diphosphate-glucuronosyltransferase (UGT)
C. Lysosomes and sulfotransferases
D. Plasma membrane and cytochrome P450 oxidoreductase
CORRECT ANSWER : B
Rationale: Phase II conjugation reactions, such as glucuronidation mediated by uridine diphosphate-
glucuronosyltransferase (UGT) enzymes, occur primarily within the smooth endoplasmic reticulum and
convert lipophilic compounds into water-soluble metabolites for excretion.
Graduate Nursing Program – 2026/2027 Academic Year EXAM
with Questions and Answers/Plus a Rationale Updated 2026
A+/Instant Download PDF
EXAM COVERAGE - 1. Pharmacokinetics and Pharmacodynamics in Advanced
Practice - 2. Autonomic and Central Nervous System Pharmacology - 3.
Cardiovascular and Renal Pharmacotherapeutics - 4. Endocrine and Metabolic
Pharmacology - 5. Antimicrobial Stewardship and Anti-infective Therapy - 6.
Psychopharmacology and Neurotransmitter Systems - 7. Immunopharmacology and
Oncologic Agents - 8. Pediatric, Geriatric, and Pregnant Population Pharmacotherapy
- 9. Toxicology, Adverse Drug Reactions, and Drug-Drug Interactions - 10. Evidence-
Based Prescribing and Regulatory Standards
1. A 68-year-old patient with chronic kidney disease stage 4 (eGFR 24 mL/min/1.73m2) is prescribed a new
medication that is 90% eliminated unchanged by the kidneys. Assuming normal liver function and a
standard adult loading dose, what is the most critical pharmacokinetic alteration expected in this patient?
A. Decreased volume of distribution due to hyperalbuminemia
B. Prolonged elimination half-life and risk of drug accumulation
C. Accelerated hepatic clearance via induction of CYP450 enzymes
D. Decreased time to reach steady-state concentration due to enhanced renal clearance
CORRECT ANSWER : B
Rationale: Renal impairment significantly reduces the clearance of drugs primarily excreted by the kidneys,
which directly increases the elimination half-life and leads to drug accumulation if the maintenance dose or
dosing interval is not adjusted. Volume of distribution and hepatic clearance are distinct physiological
parameters not directly accelerated by renal failure, and time to steady state is prolonged rather than
decreased.
2. A patient is prescribed a narrow therapeutic index drug that is a substrate for CYP3A4. Two days later, a
potent CYP3A4 inhibitor is added to their therapeutic regimen. What immediate clinical pharmacological
adjustment must the advanced practice nurse anticipate?
A. Increase the dose of the substrate drug to overcome enzyme inhibition
B. Decrease the dose or monitor serum drug levels closely to prevent toxicity
C. Switch the substrate drug to a prodrug requiring CYP3A4 activation
, D. Discontinue monitoring because inhibition decreases steady-state fluctuations
CORRECT ANSWER : B
Rationale: Inhibition of CYP3A4 decreases the metabolic breakdown of the substrate drug, raising its
plasma concentration and increasing the risk of adverse toxic effects, particularly with narrow therapeutic
index medications. Increasing the dose would exacerbate toxicity, while switching to a prodrug or
abandoning monitoring would compromise patient safety.
3. Which of the following describes the primary mechanism of action of a competitive antagonist at a G-
protein coupled receptor?
A. It binds irreversibly to the active site, permanently reducing receptor density
B. It binds to an allosteric site to induce a conformational change that prevents agonist binding
C. It binds reversibly to the active site, shifting the agonist dose-response curve to the right without
changing the maximal efficacy
D. It constitutively activates the intracellular signaling cascade independent of agonist presence
CORRECT ANSWER : C
Rationale: A competitive antagonist reversibly binds to the same active site as the agonist, meaning high
concentrations of the agonist can overcome the antagonism, shifting the dose-response curve to the right
while preserving maximal efficacy. Irreversible binding describes noncompetitive antagonism, allosteric
binding describes allosteric modulation, and constitutive activation describes inverse agonism or agonism.
4. A patient with severe hypertension is treated with a drug that exhibits zero-order elimination kinetics at
therapeutic doses. What is the defining characteristic of zero-order elimination that the clinician must
consider?
A. A constant fraction of the drug is eliminated per unit of time regardless of plasma concentration
B. A constant amount of drug is eliminated per unit of time, which can lead to disproportionate
plasma level increases with dose increments
C. The elimination half-life remains strictly proportional to the plasma concentration at any given moment
D. The rate of elimination is entirely dependent on the instantaneous volume of distribution
CORRECT ANSWER : B
Rationale: Under zero-order elimination, elimination mechanisms become saturated, meaning a constant
amount of drug is cleared per unit of time rather than a constant percentage. This nonlinear clearance can
, cause a disproportionate, potentially toxic increase in plasma concentrations with small dosage increases.
Constant fraction elimination defines first-order kinetics.
5. An advanced practice registered nurse is evaluating a drug with a high hepatic extraction ratio (greater than
0.7). Which clinical factor will most significantly influence the systemic bioavailability of this oral
medication?
A. Plasma protein binding capacity of the drug in the systemic circulation
B. Changes in hepatic blood flow rather than alterations in CYP enzyme activity
C. The pH of the distal convoluted tubule in the renal nephron
D. Competitive inhibition by plasma cholinesterases
CORRECT ANSWER : B
Rationale: Drugs with a high hepatic extraction ratio undergo extensive first-pass metabolism, making their
systemic bioavailability primarily dependent on the rate of hepatic blood flow rather than intrinsic enzymatic
capacity. Plasma protein binding and renal tubular pH affect distribution and elimination rather than oral
first-pass clearance.
6. A clinical trial investigates a novel partial agonist. Compared to a full agonist acting on the same receptor
population, what is the defining pharmacodynamic property of a partial agonist?
A. It produces zero intrinsic activity regardless of receptor occupancy
B. It elicits a submaximal maximal response even when 100 percent of the receptors are occupied
C. It acts exclusively through intracellular second-messenger degradation
D. It displays an infinite affinity for the inactive receptor conformation
CORRECT ANSWER : B
Rationale: A partial agonist binds to receptors but produces lower intrinsic efficacy and submaximal
maximum response compared to a full agonist, even at full receptor occupancy. It can also act as a
competitive antagonist in the presence of a full agonist by occupying binding sites.
7. In managing a patient with acute heart failure, a drug is administered via continuous intravenous infusion.
Approximately how many elimination half-lives are required to achieve 97 percent of the steady-state
plasma concentration?
A. One half-life
B. Three half-lives
, C. Five half-lives
D. Ten half-lives
CORRECT ANSWER : C
Rationale: Pharmacokinetically, a drug reaches approximately 97 percent of its steady-state concentration
after five elimination half-lives (representing 1 minus (0.5 to the 5th power), or 96.875 percent). One half-life
reaches 50 percent, and three half-lives reach roughly 87.5 percent.
8. When calculating the loading dose for an emergency administration of an antiarrhythmic agent, which
pharmacokinetic parameters are mathematically required?
A. Clearance and elimination half-life
B. Target peak plasma concentration and volume of distribution
C. Renal excretion rate and protein binding percentage
D. Minimum effective concentration and hepatic extraction ratio
CORRECT ANSWER : B
Rationale: The formula for a loading dose is the desired target plasma concentration multiplied by the
apparent volume of distribution. Clearance and half-life dictate the maintenance dosage regimen rather
than the initial loading dose.
9. A patient is administered a medication that undergoes extensive Phase II glucuronidation prior to excretion.
Which cellular organelle and enzyme system are primarily responsible for this metabolic process?
A. Mitochondria and monoamine oxidase
B. Endoplasmic reticulum and uridine diphosphate-glucuronosyltransferase (UGT)
C. Lysosomes and sulfotransferases
D. Plasma membrane and cytochrome P450 oxidoreductase
CORRECT ANSWER : B
Rationale: Phase II conjugation reactions, such as glucuronidation mediated by uridine diphosphate-
glucuronosyltransferase (UGT) enzymes, occur primarily within the smooth endoplasmic reticulum and
convert lipophilic compounds into water-soluble metabolites for excretion.
